BTOG 2022 | Perioperative therapies in NSCLC

Sanjay Popat, BSc, MBBS, FRCP, PhD, The Royal Marsden NHS Foundation Trust, London, UK, provides an overview of perioperative treatments for lung cancer. Adjuvant and neoadjuvant immunotherapies have proven to be beneficial, with pembrolizumab improving disease-free survival (DFS) in the Phase III KEYNOTE-091 trial (NCT02504372) and nivolumab improving event-free survival (EFS) in the Phase III CheckMate 816 trial (NCT02998528) in patients with non-small cell lung cancer (NSCLC). Whilst surgery and immunotherapy alone are insufficient, neoadjuvant nivolumab with chemotherapy have been particularly efficacious in patients with stage III resectable lung cancer in the NADIM trial (NCT03081689). This interview took place at the 20th Annual British Thoracic Oncology Group (BTOG) Conference 2022.